Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of Biolexa in adult and adolescent patients for treatment of mild to moderate atopic dermatitis

Trial Profile

Phase II trial of Biolexa in adult and adolescent patients for treatment of mild to moderate atopic dermatitis

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BioLexa (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Hoth Therapeutics

Most Recent Events

  • 21 Jun 2022 According to Hoth Therapeutics media release, the company has received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate this next phase of its BioLexa trial for patients suffering with Atopic Dermatitis
  • 21 Jun 2022 Status changed from planning to not yet recruiting according to Hoth Therapeutics media release
  • 20 Dec 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top